Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.

J Immunother Cancer · 2021 · PMC8487210 · PMID 34593617

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

showed a trendp=0.065so close (0.05 < p ≤ 0.1)

The six patients with grade 3–4 treatment-related AEs showed a trend to improved PFS and OS (p=0.065 and p=0.17, respectively; logrank test).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.